Big Pharma’s Growth Engine Is Shifting East: Why Chinese Science Now Powers the Pipeline
A decade ago, almost none of the experimental cancer drugs entering Western development pipelines originated in Chinese laboratories. Today, roughly one-third of the novel assets that major pharmaceutical companies license come from China. The transformation is no longer a niche trend or cost-saving experiment. It has become a structural feature of the global drug industry. China has overtaken or matched the United States in key measures of clinical trial volume and early-stage innovation, while Big Pharma faces a looming patent cliff that threatens hundreds of billions in revenue. The result is a wave of multi-billion-dollar partnerships that are reshaping where the next generation of medicines begins.
China’s ascent is visible in the hard data. The country now accounts for approximately 34 percent of new drugs in global clinical development, surpassing the U.S. share of around 27 percent in recent tallies. In oncology, the concentration is even sharper: Pfizer’s chief international commercial officer has noted that 40 percent of all clinical studies in the field worldwide take place in China. Trial starts have surged, particularly in early phases, supported by faster patient recruitment—often two to five times quicker than U.S. or European benchmarks in later stages—lower costs, dense networks of contract research organizations, and regulatory reforms that have streamlined timelines. Chinese biotechs run discovery programs at roughly one-third to one-half of global cost levels and complete clinical development significantly faster without, according to multiple industry analyses, sacrificing scientific rigor in many cases.
The commercial consequences appear in the licensing numbers. The value of assets out-licensed from China rose from roughly $50–52 billion in 2024 to approximately $136–137 billion in 2025, a near-tenfold increase from levels earlier in the decade. Early 2026 activity continued at a high pace, with tens of billions more committed in the opening months alone. China-origin deals have represented 30 percent or more of global licensing value in recent periods and nearly half of certain large U.S. pharmaceutical in-licensing activity. Modalities such as antibody-drug conjugates, bispecific antibodies, and other next-generation approaches feature heavily in these transactions.
Major deals illustrate the scale. Bristol Myers Squibb signed a collaboration with Jiangsu Hengrui Pharmaceuticals valued at up to $15.2 billion, covering 13 early-stage programs in oncology, hematology, and immunology. Pfizer has struck multiple agreements, including a $1.25 billion deal with 3SBio for rights to a cancer drug candidate outside China. Merck licensed a cardiovascular asset developed entirely in China for $2 billion in one notable transaction. GSK entered a broad partnership with Hengrui potentially worth $12 billion across multiple programs. AstraZeneca has pursued multi-billion-dollar arrangements with Chinese firms in metabolic disease and other areas while expanding its own R&D footprint in the country. These agreements typically grant Western companies rights outside Greater China while Chinese partners retain domestic commercialization and, in some cases, co-development options.
The drivers are both economic and scientific. Big Pharma confronts one of the steepest patent cliffs in its history. Drugs expected to generate more than $100–200 billion in annual revenue face loss of exclusivity through the early 2030s. Internal research productivity has struggled with rising costs and lengthening timelines. Chinese biotechs offer a compelling alternative: speed, cost efficiency, large and accessible patient pools for rapid enrollment, and a growing output of differentiated rather than purely imitative assets. Government policy consistency, returning talent from overseas, rising academic output (including in oncology publications and patents), and a deliberate shift from “Made in China” to “Innovated in China” have accelerated the change. Analysts describe an emerging “Trans-Pacific Biotech Relay” model in which early discovery and rapid iteration occur in China, while late-stage global trials and commercialization are handled by Western partners.
Surveys of senior industry and academic leaders reinforce the picture. The United States retains advantages in commercialization, capital markets, talent concentration in certain hubs, and technology transfer. The two countries are rated roughly equal in scientific discovery. Yet large majorities of respondents believe China is closing the gap rapidly, that any remaining U.S. lead will last a decade or less, and that China is improving faster. Some projections suggest China-originated drugs could account for a substantially higher share of FDA approvals over the next 10–15 years, rising from low single digits today toward 30 percent or more in longer-term forecasts. Revenue from innovative drugs originating in China is expected to scale dramatically by 2030 and beyond.
National security and strategic concerns are real and growing. Dependence on Chinese science for an expanding share of the innovative pipeline, layered on top of longstanding reliance on Chinese manufacturing for many active pharmaceutical ingredients, raises questions about supply-chain resilience, data access, intellectual property protection, and potential geopolitical leverage. U.S. legislative efforts have targeted outbound investment screening, restrictions on certain Chinese contractors, and broader measures aimed at reducing exposure. Industry executives and some analysts counter that overly broad restrictions risk slowing patient access to new therapies without a realistic plan to rebuild equivalent domestic capacity and speed in the near term. As one physician familiar with both systems put it, “We can’t ban our way out of this.” The momentum is structural, rooted in talent pipelines, infrastructure, consistent policy support, and market scale rather than temporary cost arbitrage alone.
Chinese firms themselves are moving up the value chain. Once primarily known for generics, contract manufacturing, and fast-follower products, many are now advancing first-in-class or highly competitive assets and, in some cases, preparing for direct global commercialization. Jiangsu Hengrui has become one of the world’s top clinical trial sponsors. Companies such as BeiGene, Innovent, 3SBio, and others have built substantial pipelines and attracted significant Western capital. Over the longer term, this evolution could reduce the availability of cost-efficient Chinese early-stage assets for Western partners that have not established their own presence in the Chinese ecosystem.
For patients, the short-term effect is more experimental medicines advancing through development at greater speed and potentially lower overall cost. For the pharmaceutical industry, the dependence creates both opportunity and vulnerability. Companies that successfully integrate Chinese science into their pipelines gain access to a high-volume source of innovation precisely when their own pipelines need replenishment. Those that cannot, or that face regulatory barriers to doing so, risk falling behind competitors. Policymakers face a parallel dilemma: how to protect strategic interests and reduce critical dependencies while avoiding measures that simply hand the advantage to other regions or delay new treatments.
The data leave little room for ambiguity. Chinese science is no longer peripheral to global pharmaceutical progress. It has become central to the industry’s near-term growth strategy and, increasingly, to the medicines that will reach patients in the United States, Europe, and beyond. Whether this shift produces a more competitive and productive global research ecosystem or creates new points of strategic friction will depend on how governments, companies, and regulators respond in the years ahead. What is already clear is that the geography of drug discovery has changed, and Big Pharma’s future growth is now tightly linked to laboratories and clinical sites thousands of miles from its traditional centers of gravity.
About The Author
